Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Handgrip strength linked to death risk among CKD patients on dialysis

27 Nov 2019

Handgrip strength (HGS) may be an easy and useful predictor of mortality among chronic kidney disease (CKD) patients receiving dialysis, reports a recent meta-analysis.

Accessing the databases of PubMed and Embase, researchers retrieved nine prospective cohort studies for inclusion in the analysis. The resulting pooled sample consisted of 2,775 CKD patients. Only reports that measured absolute or relative HGS as the sole predictor of clinical outcomes were eligible. The Newcastle-Ottawa Scale (NOS) was used to assess methodological quality.

Ten distinct datasets were available from the nine included studies. The first meta-analysis included six of these sets (n=1,996) and found that patients who had weak HGS were almost twice as likely to die than their stronger counterparts (risk ratio [RR], 1.88, 95 percent confidence intervals [CI], 1.51–2.33; p<0.001).

The effect of low HGS on mortality risk appeared to be slightly greater when assessments were performed before dialysis initiation (RR, 1.89, 95 percent CI, 1.42–2.52).

Three studies (n=779) allowed estimation of all-cause death risk according to a continuous HGS variable. Each kilogram increase in HGS led to a significant 5-percent reduction in the associated risk (RR, 0.95, 95 percent CI, 0.93–0.97; p<0.001).

Egger’s regression test found no evidence of publication bias, both for analyses of HGS as a categorical (p=0.968) and continuous (p=0.755) variable. All included studies scored at least 7 stars in the NOS, and all outcomes were measured using reliable methods. Results were robust to sensitivity analyses.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.